Skip to main content
. Author manuscript; available in PMC: 2023 Apr 28.
Published in final edited form as: Pediatr Infect Dis J. 2022 May 1;41(5):e208–e215. doi: 10.1097/INF.0000000000003494

TABLE 3.

Characteristics of Children with Severe Recurrent Bacterial Pneumonia at Time of Diagnosis

Characteristic N = 136

Age (years) <5 84 61.8%
5 to <10 41 30.1%
10 to <15 10 7.4%
≥15 1 0.7%
Median (IQR) 4.1 (1.9, 6.3)
Sex Male 75 55.1%
Female 61 44.9%
Height-for-age z-score >−2.0 32 23.5%
−2.0 to −3.0 22 16.2%
<−3.0 45 33.1%
Unknown 37 27.2%
Median (IQR) −2.7 (−3.7, −1.7)
Weight-for-age z-score >−2.0 40 29.4%
−2.0 to −3.0 30 22.1%
<−3.0 61 44.9%
Unknown 5 3.7%
Median (IQR) −2.8 (−4.6, −1.7)
Hemoglobin Normal 52 38.2%
Mild/moderate anemia 35 25.7%
Severe anemia 11 8.1%
Unknown 38 27.9%
Past severe recurrent bacterial pneumonia No 99 72.8%
Yes 37 27.2%
Past pulmonary tuberculosis No 121 89.0%
Yes 15 11.0%
Past Pneumocystis pneumonia No 132 97.1%
Yes 4 2.9%
Past symptomatic lymphoid interstitial pneumonitis No 130 95.6%
Yes 6 4.4%
Past chronic HIV-associated lung disease* No 131 96.3%
Yes 5 3.7%
Past recurrent severe bacterial infection (excluding pneumonia) No 134 98.5%
Yes 2 1.5%
CD4% ≥25% 19 14.0%
10–24% 37 27.2%
<10% 43 31.6%
Unknown 37 27.2%
Median (IQR) 11.3 (2.9, 23.0)
HIV viral load, copies/ml Undetectable 9 6.6%
Detectable 42 30.9%
Unknown 85 62.5%
Median (IQR) 25,163 (400, 138,795)
ART regimen NNRTI-based 122 89.7%
PI-based 11 8.1%
Other ART 1 0.7%
Treatment break 2 1.5%

ART, antiretroviral therapy; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

All values are n (%N) unless otherwise specified.

*

including bronchiectasis.